Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2018

Conditions
Obsessive Compulsive Disorder
Interventions
DRUG

Minocycline

Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.

OTHER

Placebo

A placebo pill will be administered twice a day (BID) for 12 weeks.

Trial Locations (2)

10021

Weill Cornell Medical Center, New York

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Weill Medical College of Cornell University

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT01695291 - Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD | Biotech Hunter | Biotech Hunter